
News|Articles|January 1, 2004
As post-tamoxifen therapy, letrozole cuts breast cancer recurrence 43%
Letrozole therapy, in follow-up to 5 years of tamoxifen treatment, significantly improves disease-free survival compared to placebo, according to a study published in The New England Journal of Medicine.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
The sleep doctor who lives with a disorder he treats
3
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
4
Recombinant shingles vaccine linked to lower cardiovascular disease risk
5













